All In Biotech

Free tool

FAERS Monitor: Children'S Alaway

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 021996 or its brand name (Children'S Alaway, Ketotifen Fumarate). Reports on generic versions are filed under their own applications.

Reports

2,730

Serious

727

27% of reports

Hospitalization

345

Death reported

31

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • eye irritation489
  • drug ineffective410
  • eye pain204
  • pruritus158
  • treatment failure149
  • ocular hyperaemia147
  • urticaria126
  • eye pruritus123
  • headache120
  • fatigue118
  • nausea113
  • condition aggravated112
  • dyspnoea112
  • instillation site pain111
  • hypersensitivity102

Reports by year received

View as table
YearReports
20045
20059
200610
200721
200873
200994
201011
201198
2012124
2013113
201423
201582
2016156
2017227
2018150
2019250
2020226
2021183
2022149
2023170
2024163
2025207
2026186

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,429 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
instillation site painSignal111361.3299.837,759
eye irritationSignal48966.060.931,061
eye pruritusSignal12328.323.83,206
eye painSignal20428.024.55,270
ocular hyperaemiaSignal14723.920.43,205
treatment failureSignal14913.911.91,772
urticariaSignal1265.84.9499
hypersensitivitySignal1024.23.5251
pruritusSignal1583.22.7237
condition aggravatedSignal1122.82.4133
drug ineffectiveSignal4102.42.2355
dyspnoea1121.51.320
headache1201.51.218
fatigue1181.21.03
nausea1131.10.91

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.